Innoviva, Inc. — filing identity and period
Important identity note: The supplied Form 10-K names Theravance, Inc. as the registrant, not Innoviva, Inc. Verify that this is the intended filing. It reports the fiscal year ended December 31, 2013; it is an annual report, not a standalone fourth-quarter filing. Financial amounts below are in U.S. dollars.
Business context and reporting period
Theravance was a biopharmaceutical company developing medicines in respiratory disease, bacterial infections, CNS/pain, and gastrointestinal disorders. Its principal commercial opportunity was a set of respiratory products partnered with GlaxoSmithKline (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA. The company also reintroduced VIBATIV in the U.S. in August 2013 and continued developing its pipeline.
In April 2013, the board approved a planned separation into Theravance and a new company, Theravance Biopharma. The proposed post-separation Theravance would retain its full royalty interests in certain GSK respiratory products and receive 15% of potential royalties on specified other programs. The 2013 financial statements do not include adjustments for the planned separation.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Total net revenue | $4.8 million | $135.8 million |
| Research and development expense | $125.2 million | $117.9 million |
| Selling, general and administrative expense | $48.4 million | $30.9 million |
| Operating loss | $168.9 million | $13.0 million |
| Net loss | $170.7 million | $18.5 million |
| Basic and diluted net loss per share | $1.67 | $0.20 |
| Cash, cash equivalents and marketable securities | $520.5 million | $343.7 million |
| Working capital | $398.8 million | $231.2 million |
| Long-term debt principal | $287.5 million | $172.5 million |
- Revenue and earnings: Annual revenue fell 96% from 2012, when $125.8 million of deferred Astellas collaboration revenue was recognized after Astellas terminated its VIBATIV agreement. 2013 revenue included $1.9 million of GSK royalties, offset by $0.7 million of amortization, and $3.6 million of other collaboration revenue. Profit margins are not meaningful given the company’s development-stage costs and very low recognized revenue.
- Quarterly context: In Q4 2013, revenue was $1.6 million and net loss was $49.9 million, compared with Q4 2012 revenue of $5.8 million and net loss of $31.3 million. 2012 quarterly results included the large Astellas revenue recognition in Q1.
- Costs: R&D expense rose 6%, mainly from external clinical-trial costs and stock compensation. SG&A rose 57%, primarily due to separation-related legal and accounting fees, VIBATIV launch costs, and employee-related costs. Separation-related external expenses were $11.0 million.
- Cash flow: Operating cash use was $129.6 million, versus $127.5 million in 2012. Investing cash use was $219.6 million, including $85.0 million of GSK milestone payments and purchases of securities. Financing provided $397.8 million, principally from the 2023 notes and common-stock issuances.
- Liquidity and debt: Management said available cash and securities were expected to fund anticipated operating needs for at least 12 months under current plans. The company issued $287.5 million of 2.125% convertible subordinated notes due 2023 and spent $36.8 million on capped-call options. The prior $172.5 million 2015 notes converted into common shares during 2013, rather than being redeemed for cash. The filing reports the 2023 notes’ fair value as $408.3 million at year-end; face principal was $287.5 million.
Material changes, outlook and risks
- Products and royalties: BREO was approved in the U.S. for COPD and launched in October 2013; RELVAR received European authorization and Japanese asthma approval; ANORO was approved in the U.S. and Canada in December. Initial BREO commercialization was described as relatively slow. 2013 GSK royalty revenue was $1.9 million net of amortization, reflecting early launches rather than established commercial scale.
- GSK milestone obligations: The company had paid $85.0 million and accrued $40.0 million at December 31, 2013 for GSK registrational and launch milestones. A further $15.0 million was recorded in January 2014; management estimated the remaining $80.0 million could be payable by the end of 2014. These amounts were capitalized as intangible assets and are being amortized.
- Pipeline developments: TD-4208 produced positive Phase 2b topline results, and the company intended to start a second Phase 2b study itself. TD-9855 failed primary endpoints in an ADHD Phase 2 study; its fibromyalgia study results were expected in the first half of 2014. The Phase 3 strategy for TD-1211 remained under review amid possible evolving FDA requirements. GSK shifted MABA development toward a once-daily combination, delaying monotherapy Phase 3.
- Planned separation: Management anticipated completing the spin-off in the second quarter of 2014 and funding Theravance Biopharma with approximately $300 million. Completion depended on regulatory, tax, contractual and other conditions; GSK’s consent arrangements would expire if the transaction was not completed by June 30, 2014. The process was already driving additional expenses and could distract management and disrupt operations. A private letter ruling from the IRS was intended, but the filing cautioned that the distribution could be taxable if tax requirements were not met.
- Operating risks: The company expected continued substantial losses and could require additional financing if plans changed. Other key risks included dependence on GSK for respiratory development and commercialization, uncertain launch uptake and reimbursement, competition, regulatory and clinical failure, and single-source supply for VIBATIV API and finished drug product. VIBATIV had only approximately $0.9 million in deferred revenue from U.S. shipments at year-end; revenue recognition was deferred until distributor sell-through.
- Other notable items: A proposed royalty participation transaction with Elan was terminated after Elan shareholders did not approve it; Theravance received a $10.0 million termination fee. Merck terminated its cardiovascular research collaboration in December 2013. The filing reported no material legal proceedings. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting.
Most important facts for investors to verify
- Confirm that the Theravance, Inc. 2013 Form 10-K is the intended filing for the Innoviva request.
- Check subsequent filings for the spin-off’s completion, final cash allocation, tax treatment, and any changes to GSK agreements.
- Track BREO/RELVAR and ANORO sales, reimbursement coverage, and royalty receipts against the modest 2013 royalty base.
- Verify the timing and payment of the remaining GSK milestones, including the $80.0 million estimated balance, and assess their cash and liquidity impact.
- Review ongoing operating cash burn, financing needs, and the terms and potential dilution of the 2023 convertible notes.
- Monitor clinical and regulatory updates for TD-4208, TD-1211, TD-9855, MABA and triple therapy, plus VIBATIV supply reliability and commercialization progress.